Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MyCode Project: the Link to Personalized Medicine

24.02.2009
Through the study of genetic links between patients and chronic diseases, Geisinger Health System researchers are hoping to gain a better understanding of how to prevent, diagnose and treat these diseases.

People differ from one another in millions of ways. For starters, there is eye color, hair color, body build, and tendencies toward certain diseases and conditions. We know that genes determine these differences. Now, we also are learning that genes affect how our bodies respond to disease. Through the study of genetic links between patients and chronic diseases, Geisinger Health System researchers are hoping to gain a better understanding of how to prevent, diagnose and treat these diseases.

A new program at Geisinger called MyCode is capitalizing on the health system’s unique ability to utilize its integrated infrastructure to link genomic information with one of the nation's most advanced electronic health record (EHR) systems and fastest growing biobanks. The result is a powerful tool that is the bridge to Geisinger's personalized medicine program – an initiative that promises to ultimately re-engineer the paradigm of healthcare from reactive to predictive and, with the help of researchers and physicians, engage patients in their personal health and wellness.

Geisinger patients learn about MyCode at Geisinger Medical Group sites and about 90 percent choose to participate. With written consent, participants agree to provide a deoxyribonucleic acid (DNA) sample – chemical material that is inherited and extracted from a blood sample - at their next scheduled blood draw. From there, the sample is linked with EHR information and routed to the system’s biobank for quick researcher access.

Since launching the MyCode pilot program two years ago, researchers have collected 20,000 DNA samples – proportionately more samples than from any other biobanking facility nationwide. Samples generally fall into two groups: those from patients seeking general health and wellness care from their family physicians and those from patients seeking specialty medical care, such as bariatric surgery.

These samples are helping Geisinger researchers gain critical insight into patients’ risk of chronic health conditions, such as abdominal aortic aneurysms (AAA), severe asthma, depression, obesity, familial ureterocoele, digoxin/phenytoin toxicity, overactive bladder syndrome and various pain conditions.

“This information will ultimately improve health by motivating people to make positive lifestyle changes, such as exercising, eating healthy, quitting smoking as well as decisions to seek further medical evaluation and preventive strategies,” said Geisinger Center for Health Research Director Walter “Buzz” Stewart, Ph.D., M.P.H.

A number of safeguards protect the privacy of participants’ genetic and EHR information. Confidentiality and subject anonymity are strictly maintained by de-identifying the samples. Samples are assigned specific identification numbers, encoded, encrypted and entered into a secure database. A governance board – with Geisinger and non-Geisinger representation - meets several times a year to audit the process.

“The goal of MyCode is to translate genetic data into specific knowledge about a disease that is clinically relevant and will enhance patient care,” said Glenn Gerhard, M.D., staff scientist and director of Geisinger’s Genomics Core. “Geisinger’s integrated healthcare delivery system, geography, as well as its electronic health record, biobank, lab, data, and basic science and population-based research programs, make this an outstanding environment for discovery."

“MyCode aims to discover genes that increase a person’s risk of chronic disease and help us understand why people respond differently to treatments,” explained Weis Center for Research Director David Carey, Ph.D. “The more we know about the causes of disease, the greater our ability to provide more effective treatment and, ultimately, prevent disease from occurring.”

According to Carey, by matching genes with a comprehensive profile of a specific chronic condition, researchers are able to study groups of patients with similar signs and symptoms and begin to predict and understand how they will respond to a specific treatment or medication.

“This project provides the opportunity to move genetics from the laboratory directly to patient care,” explained Stewart. “MyCode is driving research that promises to improve the health and healthcare of patients nationwide.”

About Geisinger Health System
Founded in 1915, Geisinger Health System (Danville, PA) is one of the nation’s largest integrated health services organizations. Serving more than two million residents throughout central and northeastern Pennsylvania, the physician-led organization is at the forefront of the country's rapidly emerging electronic health records movement. Geisinger is comprised of two medical center campuses, three hospitals, a 740-member group practice, a not-for-profit health insurance company and the Henry Hood Center for Health Research—dedicated to creating innovative new models for patient care, satisfaction and clinical outcomes.

Patricia Urosevich | Newswise Science News
Further information:
http://www.geisinger.org

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>